1. Home
  2. SPRY

as 08-29-2025 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Founded: 2015 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 1.8B IPO Year: N/A
Target Price: $28.75 AVG Volume (30 days): 2.3M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.49 EPS Growth: N/A
52 Week Low/High: $10.00 - $18.90 Next Earning Date: 08-13-2025
Revenue: $112,339,000 Revenue Growth: 22367.80%
Revenue Growth (this year): -3.81% Revenue Growth (next year): 182.40%

SPRY Daily Stock ML Predictions

Stock Insider Trading Activity of ARS Pharmaceuticals Inc. (SPRY)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Lowenthal Richard E SPRY PRESIDENT AND CEO Aug 21 '25 Sell $14.49 50,000 $724,345.00 1,196,494
Scott Kathleen D. SPRY Chief Financial Officer Aug 21 '25 Sell $15.00 12,500 $187,500.00 10,042
Tanimoto Sarina SPRY CHIEF MEDICAL OFFICER Aug 20 '25 Sell $14.09 37,656 $530,625.76 1,247,447
Tanimoto Sarina SPRY CHIEF MEDICAL OFFICER Aug 19 '25 Sell $14.03 12,344 $173,129.54 1,247,447
Karas Eric SPRY Chief Commercial Officer Jun 18 '25 Sell $16.00 15,000 $240,000.00 7,696

Share on Social Networks: